Vincenzo Pota

Prof. Vincenzo Pota

University of Campania "Luigi Vanvitelli", Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
EKEva Kirmeier
Eva Kirmeier
LELars I Eriksson
Lars I Eriksson
HLHeidrun Lewald
Heidrun Lewald
MFMalin Jonsson Fagerlund
Malin Jonsson Fagerlund
AHAndreas Hoeft
Andreas Hoeft
DZDarja Zupanĕiĕ
Darja Zupanĕiĕ

21 March 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Caterina AurilioCaterina Aurilio
Caterina Aurilio
Pasquale SansonePasquale Sansone
Pasquale Sansone
MBManlio Barbarisi
Manlio Barbarisi
Vincenzo PotaVincenzo Pota
Vincenzo Pota
LGLuca Gregorio Giaccari
Luca Gregorio Giaccari
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
Carbapenem antibiotics are the most effective antimicrobials for the treatment of infections caused by the most resistant bacteria. They belong to the category of β-lactams that include the penicillins, cephalosporins, monobactams and carbapenems. This class of antimicrobials has a broader spectrum of activity than most other beta-lactams antibiotics and are the most effective against Gram-positive and Gram-negative bacteria. All β-lactams antibiotics have a similar molecular structure: the carbapenems together with the β-lactams. This combination gives an extraordinary stability to the molecule against the enzymes inactivating the β-lactams. They are safe to use and therefore widespread use in many countries has given rise to carbapenem resistance which is a major global public health problem. The carbapenem resistance in some species is intrinsic and consists of the capacity to resist the action of antibiotics with several mechanisms: for the absence of a specific target, or an intrinsic difference in the composition of cytoplasmatic membrane or the inability to cross the outer membrane. In addition to intrinsic resistance, bacteria can develop resistance to antibiotics with several mechanisms that can be gathered in three main groups. The first group includes antibiotics with poor penetration into the outer membrane of bacterium or antibiotic efflux. The second includes bacteria that modify the target of the antibiotics through genetic mutations or post-translational modification of the target. The third includes bacteria that act with enzyme-catalyzed modification and this is due to the production of beta-lactamases, that are able to inactivate carbapenems and so called carbapenemases. In this review, we focus on the mode of action of carbapenem and the mechanisms of carbapenem resistance.

1 August 2017 in The Lancet Respiratory Medicine
Verified
Journal Article
Open access
FMFabiana Madotto
Fabiana Madotto
GBGiacomo Bellani
Giacomo Bellani
EFEddy Fan
Eddy Fan
LBLaurent Brochard
Laurent Brochard
PAPravin Amin
Pravin Amin
MVMilic Veljovic
Milic Veljovic
Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive ventilation. One of the trial's secondary aims was to characterise variations in the demographics, management, and outcome of patients with ARDS. We used the 2016 World Bank countries classification to define three major geo-economic groupings, namely European high-income countries (Europe-High), high-income countries in the rest of the world (rWORLD-High), and middle-income countries (Middle). We compared patient outcomes across these three groupings. LUNG SAFE is registered with ClinicalTrials.gov, number NCT02010073. Of the 2813 patients enrolled in LUNG SAFE who fulfilled ARDS criteria on day 1 or 2, 1521 (54%) were recruited from Europe-High, 746 (27%) from rWORLD-High, and 546 (19%) from Middle countries. We noted significant geographical variations in demographics, risk factors for ARDS, and comorbid diseases. The proportion of patients with severe ARDS or with ratios of the partial pressure of arterial oxygen (PaO2) to the fractional concentration of oxygen in inspired air (FiO2) less than 150 was significantly lower in rWORLD-High countries than in the two other regions. Use of prone positioning and neuromuscular blockade was significantly more common in Europe-High countries than in the other two regions. Adjusted duration of invasive mechanical ventilation and length of stay in the intensive-care unit were significantly shorter in patients in rWORLD-High countries than in Europe-High or Middle countries. High gross national income per person was associated with increased survival in ARDS; hospital survival was significantly lower in Middle countries than in Europe-High or rWORLD-High countries. Important geo-economic differences exist in the severity, clinician recognition, and management of ARDS, and in patients' outcomes. Income per person and outcomes in ARDS are independently associated. European Society of Intensive Care Medicine, St Michael's Hospital, University of Milan-Bicocca.

1 April 2018 in Minerva Anestesiologica
Verified
Journal Article
Closed access
EBElena Bignami
Elena Bignami
ACAlberto Castella
Alberto Castella
Vincenzo PotaVincenzo Pota
Vincenzo Pota
FSFrancesco Saglietti
Francesco Saglietti
ASAntonio Scognamiglio
Antonio Scognamiglio
MAmassimo allegri
massimo allegri
Article: Perioperative pain management in cardiac surgery: a systematic review - Minerva Anestesiologica 2018 April;84(4):488-503 - Minerva Medica - Journals

15 June 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
Maria Beatrice PassavantiMaria Beatrice Passavanti
Maria Beatrice Passavanti
LNLorenzo De Nardis
Lorenzo De Nardis
FBFabio Bosco
Fabio Bosco
Pasquale SansonePasquale Sansone
Pasquale Sansone
CACaterina Aurilio
Caterina Aurilio

27 February 2022 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
Vincenzo PotaVincenzo Pota
Vincenzo Pota
FCFrancesco Coppolino
Francesco Coppolino
ABAlfonso Barbarisi
Alfonso Barbarisi
MPMaria Beatrice Passavanti
Maria Beatrice Passavanti
CACaterina Aurilio
Caterina Aurilio
MPMaria Caterina Pace
Maria Caterina Pace
All critically ill adult patients in intensive care units (ICU) typically experience pain. Critically ill adults suffer pain of different intensities. It depends on individual characteristics, specific procedural interventions, and underlying diseases. Inadequate management of acute pain is a risk factor for the emergence of chronic pain, where the incidence is up to 33% into the ICU survivor population. For the management of pain, agitation, and delirium, several coexisting clinical practice guidelines have been published. The first problem is that the patient recovered in intensive care unit should not be able to communicate its pain state. Opioids are the analgesic drugs of choice in critically ill patients with non-neuropathic pain. All intravenous opioids have the same effects, respecting the equianalgesic table. Observational research has shown that opioids are the main analgesic treatment in over 80% of mechanically ventilated patients. It is interesting that opioid consumption in an ICU and the memory of painful experience are linked to the development of post-traumatic stress disorder after ICU discharge. In order to reduce the side effects and maintain analgesia, it is useful to associate adjuvant medications with opioids. An opportunity to improve patients’ experience in an ICU is to manage pain through multimodal approaches.